AUS
NZ
UK
CA
USA
IND
Healthcare
Can Healius (ASX:HLS) Redefine Diagnostics Growth?
April 01, 2026 09:23 PM AEDT| By SamHealius explores growth in diagnostics through strong healthcare demand, digital innovation, and expanding service networks across Australia’s evolving medical landscape.
Is This ASX 200 Healthcare Share Gearing Up for Growth?
April 01, 2026 05:10 PM AEDT| By SamHealthcare innovation continues to reshape market dynamics, with emerging companies gaining attention through clinical progress, global demand, and advanced treatment technologies within Australia’s evolving equities landscape.
ASX 20: CSL Updates Market on Ongoing Share Buy-Back Strategy
April 01, 2026 03:56 PM AEDT| By SamCSL continues its share buy-back program, highlighting strong capital management and reinforcing its position in the australian stock market.
ASX 20 : CSL Buy-Back Update Signals Strategic Capital Move
April 01, 2026 03:50 PM AEDT| By SamCSL’s ongoing share buy-back reflects strong capital management, supporting its position in the australian stock market and healthcare sector.
Can Lumos (ASX:LDX) Accelerate US Diagnostics Expansion?
April 01, 2026 03:47 PM AEDT| By SamLumos Diagnostics strengthens its US presence with a major FebriDx order, supported by regulatory progress and rising demand for rapid point-of-care diagnostic solutions.
Are All Ordinaries Trajan Shares Expanding Market Activity?
March 31, 2026 05:25 PM AEDT| By SamTrajan Group seeks quotation for additional shares, highlighting capital structure developments and healthcare sector participation within the All Ordinaries index.
ASX 200 CONNEQT Pulse Gains AARP Spotlight in Health Tech Push
March 31, 2026 03:58 PM AEDT| By SamCONNEQT Pulse gains recognition for advanced cardiovascular monitoring, strengthening its presence in the evolving healthcare technology space and highlighting the shift toward data-driven home health solutions.
All Ordinaries HiTiQ Insider Gap Draws Attention
March 31, 2026 02:04 PM AEDT| By SamHiTiQ insider positioning reflects a gap from initial investment value, highlighting market dynamics and stakeholder alignment within the healthcare technology sector.
Rhythm’s ColoSTAT Rollout Signals a New Commercial Phase
March 31, 2026 11:29 AM AEDT| By SamRhythm Biosciences has begun selling ColoSTAT in Australia, marking a major shift from development to commercial execution as the company expands access through an established pathology partnership.
Is All Ordinaries Biotech PER Advancing Cancer Therapy Research?
March 31, 2026 11:19 AM AEDT| By SamPercheron Therapeutics progresses oncology research with its HMBD therapy, highlighting regulatory engagement, biotech advancements, and presence within major ASX indices.
Alterity Advances Toward Late-Stage Trial Pathway
March 30, 2026 07:31 PM AEDT| By SamAlterity Therapeutics progresses toward late-stage clinical development following regulatory alignment, reinforcing its strategy in neurological drug innovation and strengthening its pathway for future trial execution.
Stock Market Spotlight: Breakthrough in Wound Care as (ASX:ARX) Advances Trial
March 30, 2026 07:14 PM AEDT| By SamAroa Biosurgery advances wound care innovation with Symphony trial completion, showcasing improved healing outcomes and strengthening its clinical and commercial outlook in global healthcare markets.
Market Watch ASX 100 Highlights Key Sector Activity
March 30, 2026 03:57 PM AEDT| By SamASX 100 reflects sector-wide activity with CSL and key industries contributing to diversified market participation within the All Ordinaries framework.
Blinklab ASX 300 Healthcare Operations and ASX Ordinaries Stocks
March 29, 2026 04:33 AM AEDT| By SamBlinklab healthcare operations focus on digital neurological screening systems and structured resource allocation within the ASX healthcare ecosystem and broader market framework.
Telix Pharmaceuticals Update Sparks ASX Healthcare Momentum Shift
March 29, 2026 04:31 AM AEDT| By SamTelix Pharmaceuticals update highlights growing momentum in ASX healthcare sector as regulatory progress and innovation strengthen biotechnology outlook across Australian market landscape and investor attention expands steadily.
Unlock PME Valuation Signals Ahead of ASX 200 Momentum
March 29, 2026 04:27 AM AEDT| By Team Kalkine MediaPME reflects healthcare imaging strength, institutional integration, and digital transformation themes influencing Australian equities, structured valuation analysis, and long-term healthcare technology positioning across markets.
Healthcare Innovator 4DMedical in ASX 300 Gains Attention
March 29, 2026 04:24 AM AEDT| By Team Kalkine Media4DMedical advances respiratory imaging technology while strengthening operations through a major capital raise, supporting global expansion and healthcare innovation within the ASX 300 landscape.
4DMedical Rallies as Expansion Story Gains Traction
March 27, 2026 09:05 PM AEDT| By Sam4DMedical re-enters focus after a capital raise, with its imaging innovation and expansion strategy shaping valuation discussions and market sentiment.
ResMed & Netwealth: A Fresh Look at Valuation Trends
March 27, 2026 07:54 PM AEDT| By SamResMed and Netwealth shares are drawing attention as valuation metrics shift below historical trends, offering insights into business resilience and evolving market dynamics.
Lumos Diagnostics Gains FDA Nod to Expand US Reach
March 27, 2026 05:20 PM AEDT| By SamLumos Diagnostics advances US expansion after regulatory clearance, enabling wider clinical adoption of its rapid test and supporting growth through strategic funding and operational scale-up.
Advertise your brand on Kalkine Media